Becton, Dickinson and Company $BDX Shares Acquired by Goldman Sachs Group Inc.

Key Points

• Goldman Sachs Group Inc. increased its stake in Becton, Dickinson and Company by 18.5% during the first quarter, owning 929,180 shares valued at approximately $212.8 million.
• Becton, Dickinson reported a 10.4% year-over-year revenue increase, totaling $5.51 billion, with earnings per share of $3.68, surpassing analysts' expectations.
• The company recently announced a quarterly dividend of $1.04, providing an annualized yield of 2.2%, to be paid to shareholders on September 30th.

Goldman Sachs Group Inc. raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 18.5% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 929,180 shares of the medical instruments supplier's stock after purchasing an additional 145,247 shares during the quarter. Goldman Sachs Group Inc. owned 0.32% of Becton, Dickinson and Company worth $212,838,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. Northcape Wealth Management LLC grew its position in shares of Becton, Dickinson and Company by 0.5% during the first quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier's stock worth $2,248,000 after buying an additional 51 shares in the last quarter. Alpha Omega Wealth Management LLC grew its holdings in Becton, Dickinson and Company by 5.7% during the 1st quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier's stock worth $225,000 after acquiring an additional 53 shares in the last quarter. Brady Family Wealth LLC increased its position in shares of Becton, Dickinson and Company by 1.2% in the 1st quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier's stock worth $989,000 after purchasing an additional 53 shares during the last quarter. Diversified Trust Co raised its stake in shares of Becton, Dickinson and Company by 4.7% in the 1st quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier's stock valued at $272,000 after purchasing an additional 53 shares in the last quarter. Finally, REAP Financial Group LLC grew its stake in Becton, Dickinson and Company by 75.3% in the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after purchasing an additional 55 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares of the company's stock, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Claire Fraser sold 863 shares of the business's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $192.30, for a total value of $165,954.90. Following the completion of the sale, the director directly owned 23,143 shares in the company, valued at $4,450,398.90. This represents a 3.59% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $188.57 on Thursday. The stock has a market cap of $54.05 billion, a P/E ratio of 33.91, a P/E/G ratio of 1.42 and a beta of 0.27. The firm's 50-day simple moving average is $185.95 and its 200 day simple moving average is $192.31. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.51 billion for the quarter, compared to analysts' expectations of $5.50 billion. During the same quarter last year, the company earned $3.50 EPS. Becton, Dickinson and Company's quarterly revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Equities analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio is 74.82%.

Analyst Ratings Changes

A number of research analysts have commented on BDX shares. Wall Street Zen raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Barclays decreased their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a report on Tuesday, June 3rd. Wells Fargo & Company increased their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a report on Friday, August 8th. Citigroup downgraded shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and reduced their price target for the stock from $217.00 to $185.00 in a research report on Thursday, May 22nd. Finally, Piper Sandler reaffirmed a "neutral" rating and set a $200.00 price objective (up previously from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Four research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $211.44.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.